Stockscreener 앱 받기
1.2009
0.92%
0.0109
전일 마감가:
$1.19
열려 있는:
$1.18
하루 거래량:
14,230
Relative Volume:
0.26
시가총액:
$11.83M
수익:
-
순이익/손실:
$-18.98M
주가수익비율:
-0.4209
EPS:
-2.8535
순현금흐름:
$-14.55M
1주 성능:
+11.19%
1개월 성능:
+2.64%
6개월 성능:
-25.41%
1년 성능:
-42.54%
1일 변동 폭
$1.18
$1.20
1주일 범위
$1.06
$1.25
52주 변동 폭
$0.88
$2.73
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.20 | 11.73M | 0 | -18.98M | -14.55M | -2.8535 |
VRTX
Vertex Pharmaceuticals Inc
|
521.37 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.46 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.13 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
960.68 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.17 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-18 | 개시 | Laidlaw | Buy |
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
After a 1-for-25 reverse stock split, Valion Bio (VBIO) executive reports a stock-unit settlement. - Stock Titan
IN8bio to Present at Sidoti Small-Cap Virtual Conference - GlobeNewswire Inc.
TELA Bio Received Notice of Delisting - TradingView
Upstream Bio (UPB) exec offloads shares to cover taxes - Stock Titan
Inmune Bio (NASDAQ: INMB) grants 100,000 stock options to new director - stocktitan.net
$2.50 share warrants bring new cash to Cabaletta Bio (CABA) - Stock Titan
Kala Bio Secures 5-Year Exclusive U.S. Distribution for Ophthalmic Genetic Testing With Virotek - tradingview.com
Kyntra Bio (KYNB) CFO holds 4,355 shares after tax withholding - Stock Titan
KALA BIO (NASDAQ: KALA) sets Sept. 19 cutoff for 2026 shareholder proposals - Stock Titan
Gossamer Bio announces 1-for-80 reverse stock split, authorized shares cut to 50M - TradingView
Braveheart Bio Completes IPO with $122.8 Million in Gross Proceeds - Minichart
Adicet Bio posts September 2026 investor presentation outlining prula-cel and ADI-212 clinical timelines - TradingView
Braveheart Bio (NASDAQ:BRVE) Trading Up 8%Should You Buy? - MarketBeat
PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure - BioSpace
GRI Bio posts Phase 2a IPF biomarker and safety data; +99 mL placebo‑adj FVC, supports longer study - TradingView
Experimental IPF pill from GRI Bio (GRI) boosts lung function in 12 weeks as company eyes 52-week study - stocktitan.net
Cough during treatment was 0% with GRI Bio's drug, versus 25% on placebo - stocktitan.net
symbol__ Stock Quote Price and Forecast - CNN
Investor group in Valion Bio (VBIO) shifts to passive stake - Stock Titan
Biotech Gossamer Bio (NASDAQ: GOSS) markets $125M more in private securities - Stock Titan
[425] Passage BIO, Inc. Business Combination Communication | PASG SEC FilingForm 425 - Stock Titan
Valion Bio Raises $7.74 Million Via Series B/C Preferred and Warrants From 3i - TradingView
2,426,857 Boundless Bio (NASDAQ: BOLD) shares held by Zachary Hornby - stocktitan.net
KALA BIO Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
FDA clears Adicet Bio's application to study a gene-edited prostate cancer therapy - Stock Titan
Gossamer Bio (NASDAQ: GOSS) links CEO options to FDA decision on seralutinib - Stock Titan
Valion Bio, Inc. SEC Filing (Aug 24, 2026) - Stock Titan
Gossamer Bio (NASDAQ: GOSS) has 6% of its stock under D. E. Shaw’s reported influence - Stock Titan
TBIO | TELESIS BIO INC Insider Trading - Quiver Quantitative
Gossamer Bio Lines Up Up To $250 Million Private Placement With Milestone-Triggered Warrants - TradingView
3i injects cash into Valion Bio (VBIO) under tight ownership cap - Stock Titan
Climb Bio Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Tech workers may be better off selling their company stock - Business Insider
TELA Bio (TELA) stake: Nantahala group reports 12.94% ownership of 5.79M shares - Stock Titan
Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership - Stock Titan
Climb Bio, Inc. (CLYM): MPM BioImpact LLC reports 0% ownership in amendment - Stock Titan
Point72 discloses 4.95% Q32 Bio Inc. (QTTB) holding in Schedule 13G/A - Stock Titan
Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares - Stock Titan
Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake - Stock Titan
Q32 Bio Inc. (QTTB) major holders cut reported stake to 0% - Stock Titan
Caballeta Bio (CABA) stake: Bain Capital Life Sciences reports 9.99% position - Stock Titan
Cormorant Asset Management (CABA) discloses 10M-share Cabaletta Bio stake - Stock Titan
Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan - Stock Titan
Instil Bio (Nasdaq: TIL) trims Q2 2026 loss and extends cash runway - Stock Titan
BIO-key International (BKYI) secures $2.51M and issues 1.24M new warrants in financing - Stock Titan
Palisade Bio (PALI): Soleus group reports 7.5% stake, 13.1M shares held - Stock Titan
Cabaletta Bio (CABA) lifts cash to $225M while advancing rese-cel toward BLA - Stock Titan
Valion Bio, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
Adage Capital discloses 8.43% Cabaletta Bio (CABA) stake including warrant shares - Stock Titan
Cabaletta Bio (CABA): Norges Bank reports 5.382% ownership of 8.78M shares - Stock Titan
BRVE SEC FilingsBraveheart Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.82%
0.45%
자본화:
|
볼륨(24시간):